07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly reduced allergen-induced LAR from baseline...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

ASM8: Completed Phase II enrollment

Pharmaxis completed enrollment of 16 adult asthmatics in a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial evaluating once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia  ...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase II started

Pharmaxis began a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial in 16 adult asthmatics to evaluate once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product:...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc....
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Topigen, NicOx, Pharmaxis deal

Pharmaxis will acquire Topigen in a stock deal valued at A$8.6 million (US$8 million) up front and A$13.5 million (US$12.6 million) in potential milestones, based on Pharmaxis' close of A$2.70 on Jan. 11, before the...
01:20 , Jan 13, 2010 |  BC Extra  |  Company News

Pharmaxis to acquire Topigen

Pharmaxis Ltd. (ASX:PXS) will acquire Topigen Pharmaceuticals Inc. (Montreal, Quebec) in a stock deal valued at A$8.6 million ($8 million) up front and A$13.5 million ($12.6 million) in potential milestones, based on Pharmaxis' close of...
08:00 , Jan 12, 2009 |  BC Week In Review  |  Clinical News

TPI ASM8: Phase II data

In the double-blind, European Phase II TPI ASM8-205 trial in 18 patients with mild to moderate asthma, inhaled TPI ASM8 once daily for 14 days missed the primary endpoint of an allergen-induced maximum decrease in...
01:53 , Jan 10, 2009 |  BC Extra  |  Clinical News

Topigen's TPI ASM8 misses Phase II endpoint

Topigen (Montreal, Quebec) said inhaled TPI ASM8 once daily for 14 days missed the primary endpoint of an allergen-induced maximum decrease in FEV1 for late asthmatic response vs. placebo in the Phase II TPI ASM8-205...
07:00 , Oct 9, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune Granulocyte/macrophage colony-stimulating factor (GM-CSF) A study in cell culture and in mice suggests that inhibiting GM-CSF expression may...